Brief-AstraZeneca's Efzimfotase alfa Granted Priority Review In U.S.
AZN•FDA grants priority review for Efzimfotase alfa
-
AstraZeneca PLC AZN.L:
-
Efzimfotase alfa granted priority review in the U.S. as treatment for patients with hypophosphatasia aged 2 years and older
-
AstraZeneca said the FDA decision on Efzimfotase alfa is expected in the first half of 2027
